Brief: Xvivo Gets Market Approval From FDA For Steen Solution And XPS
April 29 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* XVIVO HAS RECEIVED MARKET APPROVAL (PMA) FROM THE FDA FOR
STEEN
SOLUTION™ AND XPS™
* ON APRIL 26, 2019 XVIVO RECEIVED PREMARKET APPROVAL (PMA)
FROM
FDA FOR PRODUCTS XPS™ AND STEEN SOLUTION™ FOR SALE ON AMERICAN
MARKET
Source text for Eikon: ID:nWkrzFr4C
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength